Hikma Pharmaceuticals PLC (LSE:HIK)
£ 19.78 -0.05 (-0.25%) Market Cap: 4.39 Bil Enterprise Value: 5.15 Bil PE Ratio: 29.43 PB Ratio: 2.52 GF Score: 92/100

Hikma Pharmaceuticals PLC at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 05:45PM GMT
Release Date Price: £16.81 (+0.45%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the Hikma presentation. You're going to hear from Bassam Kanaan, Corporate Development and M&A. And then we're going to do a breakout setup here, where we're also going to be joined by Susan Ringdal, Global Affairs and Strategic Planning. Thanks very much for coming today and looking forward to the presentation.

Bassam Wael Rushdi Kanaan
Hikma Pharmaceuticals PLC - EVP of Corporate Development and M&A

Good morning, everyone. I'm very happy to be here. The usual disclaimer to start with. Actually, I've been in Hikma for 20 years. And in this period of time, we went from a small company founded in Jordan, with sales of less than $100 million to a global company listed on the London Stock Exchange with sales of $2.5 billion. It has been an incredible journey for me and a privilege to be part of this growth. Today, I truly believe that our business is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot